Vaseeha Banu T.S., Sandhya K.V., K.N. Jayaveera
Email ID Not Available
Vaseeha Banu T.S.1, Sandhya K.V.2 and K.N. Jayaveera3
1Dept. of Pharmaceutics, M.M.U College of Pharmacy, K.K. Doddi, Ramanagara- 562159. Karnataka
2 Dept. of Pharmaceutics, T. John College of Pharmacy, Bannerghatta Road, Bangalore- 560083. Karnataka
3 Dept. of Chemistry, Jawaharlal Nehru Technological University Anantapur, Anantapur- 515002, Andhra Pradesh.
Volume - 7,
Issue - 1,
Year - 2014
Stable angina is characterized by chest discomfort rather than actual pain. The main goal of the treatment is to control symptoms, slow progression of the disease and reduction of major cardiovascular events. Ivabradine HCl (IBH) is a new first specific If channel blocker used to treat stable angina. In our present investigation, an attempt has been made to formulate transdermal drug delivery system of IBH to treat stable angina. The suitability of drug with respect to lower dose, low molecular weight and short half life makes this drug as a suitable candidate for administration via transdermal route. Transdermal films of IBH have been prepared by solvent casting technique using different ratios of varying degree of hydrophilic and hydrophobic polymers namely hydroxypropyl methyl cellulose (HPMC), ethyl cellulose (EC) and polyvinyl pyrrolidine (PVP) (blend ratios viz; 0.5:1.5, 1:1 and 1.5:0.5% w/v). Propylene glycol (30% w/w) and Isopropyl myristate and oleic acid (2:0.5% w/w) was incorporated as plasticizer and permeation enhancer respectively. The effect of polymers on the various physicochemical characteristics and ex-vivo skin permeation studies were evaluated. The formulations exhibited uniform thickness, weight and good uniformity in drug content. Moisture content and moisture absorption were increased for the patches containing higher amount of PVP due to its hydrophilic nature, the results of water vapour transmission rate revealed that the transdermal films were permeable to water vapours. Ex-vivo release studies showed zero order release of the drug from all the patches and the mechanism of release was diffusion mediated. Moreover, the release of the drug was sustained and extended over a period of 24 h in all the formulations. On the basis of technical properties and ex-vivo release formulation F7 emerged as the most satisfactory formulation. The stability studies revealed no morphological changes in formulations and an insignificant variation in drug content. Furthermore the results of skin irritation test revealed that the patches were seemingly free of any skin irritation. Thus it could be concluded that the transdermal films proved to be a promising drug delivery system for IBH with more patient compliance in the treatment of stable angina.
Cite this article:
Vaseeha Banu T.S., Sandhya K.V., K.N. Jayaveera. Formulation and Evaluation of Transdermal Drug Delivery Systems of Ivabradine Hydrochloride. Research J. Pharm. and Tech. 7(1): Jan. 2014; Page 01-07.
Vaseeha Banu T.S., Sandhya K.V., K.N. Jayaveera. Formulation and Evaluation of Transdermal Drug Delivery Systems of Ivabradine Hydrochloride. Research J. Pharm. and Tech. 7(1): Jan. 2014; Page 01-07. Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2014-7-1-1